

# Maaïke van Putten

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2722231/publications.pdf>

Version: 2024-02-01

40  
papers

1,311  
citations

430442

18  
h-index

377514

34  
g-index

46  
all docs

46  
docs citations

46  
times ranked

2061  
citing authors

#	ARTICLE	IF	CITATIONS
1	The therapeutic potential of soluble activin type IIB receptor treatment in a limb girdle muscular dystrophy type 2D mouse model. <i>Neuromuscular Disorders</i> , 2022, 32, 419-435.	0.3	1
2	Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model. <i>Scientific Reports</i> , 2021, 11, 9779.	1.6	6
3	Discovering fiber type architecture over the entire muscle using data-driven analysis. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 1240-1249.	1.1	5
4	Uniform sarcolemmal dystrophin expression is required to prevent extracellular microRNA release and improve dystrophic pathology. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 578-593.	2.9	24
5	Sensitive and reliable evaluation of single-cut sgRNAs to restore dystrophin by a GFP-reporter assay. <i>PLoS ONE</i> , 2020, 15, e0239468.	1.1	8
6	A data-driven methodology reveals novel myofiber clusters in older human muscles. <i>FASEB Journal</i> , 2020, 34, 5525-5537.	0.2	7
7	The use of genetically humanized animal models for personalized medicine approaches. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, dmm041673.	1.2	22
8	Mouse models for muscular dystrophies: an overview. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, dmm043562.	1.2	30
9	Moving neuromuscular disorders research forward: from novel models to clinical studies. <i>DMM Disease Models and Mechanisms</i> , 2020, 13, .	1.2	6
10	Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the mdx Mouse Model for Duchenne Muscular Dystrophy. <i>Frontiers in Behavioral Neuroscience</i> , 2020, 14, 629043.	1.0	3
11	Detailed genetic and functional analysis of the hDMDdel52/mdx mouse model. <i>PLoS ONE</i> , 2020, 15, e0244215.	1.1	15
12	Dystrophin deficiency leads to dysfunctional glutamate clearance in iPSC derived astrocytes. <i>Translational Psychiatry</i> , 2019, 9, 200.	2.4	18
13	Cross-sectional study into age-related pathology of mouse models for limb girdle muscular dystrophy types 2D and 2F. <i>PLoS ONE</i> , 2019, 14, e0220665.	1.1	14
14	Nonclinical Exon Skipping Studies with 2'-O-Methyl Phosphorothioate Antisense Oligonucleotides in mdx and mdx-utrn <sup>+/+</sup> Mice Inspired by Clinical Trial Results. <i>Nucleic Acid Therapeutics</i> , 2019, 29, 92-103.	2.0	9
15	A modified diet does not ameliorate muscle pathology in a mouse model for Duchenne muscular dystrophy. <i>PLoS ONE</i> , 2019, 14, e0215335.	1.1	2
16	Natural disease history of the D2mdx mouse model for Duchenne muscular dystrophy. <i>FASEB Journal</i> , 2019, 33, 8110-8124.	0.2	88
17	High-throughput data-driven analysis of myofiber composition reveals muscle-specific disease and age-associated patterns. <i>FASEB Journal</i> , 2019, 33, 4046-4053.	0.2	2
18	Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice. <i>Neuromuscular Disorders</i> , 2018, 28, 427-442.	0.3	15

#	ARTICLE	IF	CITATIONS
19	227 th ENMC International Workshop: Neuromuscular Disorders, 2018, 28, 185-192.	0.3	5
20	Voluntary exercise improves muscle function and does not exacerbate muscle and heart pathology in aged Duchenne muscular dystrophy mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 125, 29-38.	0.9	15
21	Natural disease history of the dy <sup>2J</sup> mouse model of laminin $\beta$ 2 (merosin)-deficient congenital muscular dystrophy. <i>PLoS ONE</i> , 2018, 13, e0197388.	1.1	6
22	Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy. <i>PLoS ONE</i> , 2018, 13, e0194636.	1.1	10
23	A dystrophic Duchenne mouse model for testing human antisense oligonucleotides. <i>PLoS ONE</i> , 2018, 13, e0193289.	1.1	44
24	Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy. <i>Scientific Reports</i> , 2017, 7, 12575.	1.6	123
25	New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration. <i>FASEB Journal</i> , 2017, 31, 238-255.	0.2	24
26	PABPN1-Dependent mRNA Processing Induces Muscle Wasting. <i>PLoS Genetics</i> , 2016, 12, e1006031.	1.5	41
27	Accurate Dystrophin Quantification in Mouse Tissue; Identification of New and Evaluation of Existing Methods. <i>Journal of Neuromuscular Diseases</i> , 2016, 3, 77-90.	1.1	13
28	Environmental 24-hr Cycles Are Essential for Health. <i>Current Biology</i> , 2016, 26, 1843-1853.	1.8	101
29	Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models. <i>European Journal of Neuroscience</i> , 2016, 43, 1623-1635.	1.2	59
30	Evaluation of 2'-Deoxy-2'-fluoro Antisense Oligonucleotides for Exon Skipping in Duchenne Muscular Dystrophy. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e265.	2.3	20
31	Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9. <i>Skeletal Muscle</i> , 2015, 5, 37.	1.9	31
32	What Can We Learn From Assisted Bicycle Training in a Girl With Dystrophinopathy? A Case Study. <i>Journal of Child Neurology</i> , 2015, 30, 659-663.	0.7	7
33	Preclinical Studies on Intestinal Administration of Antisense Oligonucleotides as a Model for Oral Delivery for Treatment of Duchenne Muscular Dystrophy. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e211.	2.3	13
34	Low dystrophin levels in heart can delay heart failure in mdx mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2014, 69, 17-23.	0.9	47
35	Assessing Functional Performance in the <i>em&gt;</i> Mdx <i>&lt;/em&gt;</i> Mouse Model. <i>Journal of Visualized Experiments</i> , 2014, .	0.2	127
36	Low dystrophin levels increase survival and improve muscle pathology and function in dystrophin/utrophin double-knockout mice. <i>FASEB Journal</i> , 2013, 27, 2484-2495.	0.2	94

#	ARTICLE	IF	CITATIONS
37	Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains. <i>Neuromuscular Disorders</i> , 2012, 22, 406-417.	0.3	65
38	The Effects of Low Levels of Dystrophin on Mouse Muscle Function and Pathology. <i>PLoS ONE</i> , 2012, 7, e31937.	1.1	96
39	Opportunities and challenges for the development of antisense treatment in neuromuscular disorders. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1025-1037.	1.4	11
40	A 3 months mild functional test regime does not affect disease parameters in young mdx mice. <i>Neuromuscular Disorders</i> , 2010, 20, 273-280.	0.3	38